Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/053358external-prioritypatent/WO2010019540A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2011000037A1publicationCriticalpatent/TN2011000037A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention pertains to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof or a pyrimidylaminobenzamide of formula I wherein the radicals and symbols are as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of medicament for treating pulmonary arterial hypertension (PAH), especially in patients who failed prior PAH therapy.
TN2011000037A2009-08-112011-01-26Treatment of pulmonary arterial hypertension
TN2011000037A1
(en)
Substituted (2-oxo-1,3-oxazolidin-5-yl)methyl-thiophene-2-carboxamides, process for preparing same and use thereof for preparing medicaments for the treatment and/or prophylaxis of diseases